Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety Extension of Teplizumab in Children and Adolescents with Recent-Onset Type 1 Diabetes Mellitus
2024-516543-26-00Phase 3Authorised
- Sponsor
- Provention Bio
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of teplizumab in diabetes mellitus type 1 (T1D), sponsored by Provention Bio. Primary endpoint: Incidence of adverse events, serious adverse events and adverse events of special interest. Planned start Jul 2021; status: authorised.
02
Drugs
teplizumab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2024-516543-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516543-26-00.